Novartis's Recent Performance Adds Credibility to New Outlook -- Market Talk

Dow Jones11-20

0851 GMT - Novartis's new midterm outlook is better than anticipated and the company's recent track-record of delivering on expectations suggests forecasts could raise as a result, Vontobel's Stefan Schneider says in a research note. "The management has consistently demonstrated strong execution of their given commitments, delivering as promised in recent years. Accordingly, the new outlook offers potential for higher estimates," the analyst says. The company rolled forward its midterm target to the 2025-30 period, a period during which psoriasis drug Cosentyx is set to lose patent protection, the analyst says. Moreover, it raised its peak sales guidance for two important drugs, breast-cancer medicine Kisqali and leukemia treatment Scemblix. Shares rise 0.6% to 102.86 Swiss francs. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

November 20, 2025 03:51 ET (08:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584818162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584818162","market":"sg","top_or_hot":-1,"title":"Novartis's Recent Performance Adds Credibility to New Outlook -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0851 GMT - Novartis's new midterm outlook is better than anticipated and the company's recent track-record of delivering on expectations suggests forecasts could raise as a result, Vontobel's Stefan Schneider says in a research note. \"The management has consistently demonstrated strong execution of their given commitments, delivering as promised in recent years. Accordingly, the new outlook offers potential for higher estimates,\" the analyst says. The company rolled forward its midterm target to the 2025-30 period, a period during which psoriasis drug Cosentyx is set to lose patent protection, the analyst says. Moreover, it raised its peak sales guidance for two important drugs, breast-cancer medicine Kisqali and leukemia treatment Scemblix. Shares rise 0.6% to 102.86 Swiss francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2025 03:51 ET (08:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis's Recent Performance Adds Credibility to New Outlook -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis's Recent Performance Adds Credibility to New Outlook -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-20 16:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0851 GMT - Novartis's new midterm outlook is better than anticipated and the company's recent track-record of delivering on expectations suggests forecasts could raise as a result, Vontobel's Stefan Schneider says in a research note. \"The management has consistently demonstrated strong execution of their given commitments, delivering as promised in recent years. Accordingly, the new outlook offers potential for higher estimates,\" the analyst says. The company rolled forward its midterm target to the 2025-30 period, a period during which psoriasis drug Cosentyx is set to lose patent protection, the analyst says. Moreover, it raised its peak sales guidance for two important drugs, breast-cancer medicine Kisqali and leukemia treatment Scemblix. Shares rise 0.6% to 102.86 Swiss francs. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2025 03:51 ET (08:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584818162","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584818162","pubTimestamp":1763628660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0851 GMT - Novartis's new midterm outlook is better than anticipated and the company's recent track-record of delivering on expectations suggests forecasts could raise as a result, Vontobel's Stefan Schneider says in a research note. \"The management has consistently demonstrated strong execution of their given commitments, delivering as promised in recent years. Accordingly, the new outlook offers potential for higher estimates,\" the analyst says. The company rolled forward its midterm target to the 2025-30 period, a period during which psoriasis drug Cosentyx is set to lose patent protection, the analyst says. Moreover, it raised its peak sales guidance for two important drugs, breast-cancer medicine Kisqali and leukemia treatment Scemblix. Shares rise 0.6% to 102.86 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4588":"碎股","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","BK4578":"CAR-T","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","NVS":"诺华","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"诺华最近的业绩为新前景增添了可信度——市场谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"0851 GMT - Novartis's new midterm outlook is better than anticipated and the company's recent track-record of delivering on expectations suggests forecasts could raise as a result, Vontobel's Stefan Schneider says in a research note. \"The management has consistently demonstrated strong execution of their given commitments, delivering as promised in recent years. Accordingly, the new outlook offers potential for higher estimates,\" the analyst says. The company rolled forward its midterm target to the 2025-30 period, a period during which psoriasis drug Cosentyx is set to lose patent protection, the analyst says. Moreover, it raised its peak sales guidance for two important drugs, breast-cancer medicine Kisqali and leukemia treatment Scemblix. Shares rise 0.6% to 102.86 Swiss francs. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 03:51 ET (08:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584818162","isCrawlerRequest":true}